The orthopedic giants, like J&J MedTech (formerly DePuy-Synthes), love to play the innovation card, strutting onto the stage like tech startups while moving with the agility of a dinosaur in a tar pit.
Their latest act?
The Polyphonic AI Fund for Surgery, a dazzling showcase featuring Nvidia and AWS as high-tech props. Read the press release here.
It’s a masterclass in corporate theater—flush with buzzwords, a dash of funding, and a loud cry of “behold our innovation!” Yet, beneath the AI hype and startup posturing, it’s a slick maneuver to steal the spotlight while tightening their grip on the medtech crown. With their Polyphonic platform, launched in 2024, J&J is cherry-picking external ideas to fuel their ecosystem, all while keeping true disruption at arm’s length.
Here’s why this move is more about control than creativity.
It’s the corporate equivalent of a dad trying to TikTok his way into coolness—lots of buzzwords, a sprinkle of cash, and a whole lot of “look at us innovating!” But behind the AI hype and startup swagger, it’s just another calculated move to hog the spotlight while keeping their iron grip on the medtech throne.
In this case, J&J is strategic...
